The global sterile filtration market is projected to generate USD 19,111.3 million revenue by 2030, advancing at a CAGR of 11.0% during 2024–2030. This can be ascribed to the rising expenditure of the pharmaceutical and biotechnology industries on R&D and the increasing incidence of chronic diseases. Moreover, the need to preserve quality and shelf life drives the usage of these technologies in the food and beverage sector.
The changing lifestyles and climate contribute to chronic diseases, including cancer, cardiovascular, respiratory, and neurodegenerative diseases. For instance, approximately 18 million people die per year of heart diseases, followed by cancer (around 10 million), chronic respiratory diseases (around 5 million), and diabetes (2.0 million [including kidney disease deaths caused by diabetes]). The rising number of people with such diseases is driving the healthcare sector to be more advanced, to develop better drugs.
Furthermore, with the increasing drug development and manufacturing capabilities of pharma and biopharma companies, the chances of the contamination and a lower quality of the drugs also rise. Since these factors may directly harm the consumer, it is necessary for governments to ensure that only high-quality products are developed, manufactured, and distributed.
Additionally, the failure of manufacturers and distributors to ensure drug sterilization and quality drives the adoption of numerous filtration technologies in order to increase the feasibility and reliability of drugs. Focus on building a strong and comprehensive regulatory framework is needed to ensure quality medicines. The use of sterile filters over non-sterile filters has also attracted attention due to the former’s higher efficiency. Essentially, the market expansion is driven by the government and private expenditure on drug development and processes, methods, and techniques to validate the quality and effectiveness of all medications.
The polyethersulfone (PES) category held the largest share in 2023 because this material is highly suitable for the filtration and clarification of pharmaceutical and biological solutions. Interchangeable PES membranes are used in applications such as sample preparation, filtration, and infusion therapy because of their ability to eliminate fine particles, bacteria, and fungi. Moreover, they are inherently hydrophilic membranes that quickly wet and lead to faster filtration with a high flow rate and efficiency. In addition, owing to their longer life and low maintenance requirements, PES membranes have become widespread in the treatment of wastewater.
Pharmaceutical and biopharmaceutical companies will dominate the market during the forecast period due to their increasing count and investment in R&D. In 2021, the pharmaceutical industry spent approximately USD 85 billion on drug discovery and clinical testing, which grew to USD 140 billion the next year.
Geographically, North America is expected to grow with a CAGR of about 10.8% during the forecast period. This can be attributed to the rising prevalence of chronic diseases and increasing number of biopharmaceutical companies. The strong concentration of food and beverage and pharma companies on ensuring a high product quality are responsible for the region’s significant market share. Moreover, in recent years, many life sciences and pharmaceutical companies and government organizations have increased their investment in drug R&D activities.
Asia-Pacific is one of the fastest-growing regional markets, due to the huge burden of chronic diseases, such as cardiovascular diseases, diabetes, and cancer, and the resulting increase in pharmaceutical R&D expenditure. Furthermore, due to the increasing number of pharmaceutical companies, research and development activities will increase, which will eventually drive the market growth.
The major players operating in the sterile filtration market include Merck KGaA, Danaher Corporation, Sartorius AG, 3M, Pall Corporation, Parker-Hannifin Corporation, Thermo Fisher Scientific Inc., Porvair Filtration Group, Sterlitech Corporation, and Alfa Laval.